By Colin Kellaher
Trading in shares of Opthea is halted in the U.S. and Australia ahead of planned update by the clinical-stage biopharmaceutical company on a late-stage study of its lead product candidate sozinibercept in wet age-related macular degeneration, or wet AMD.
In a filing with the Australian Securities Exchange Monday, Opthea requested the trading halt pending an announcement related to top-line results of a Phase 3 study of sozinibercept in combination with aflibercept in wet AMD, an eye condition that causes blurred vision or reduced central vision.
The ASX said the halt will remain in place until the start of trading Wednesday unless Opthea issues an announcement sooner.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 17, 2025 11:26 ET (15:26 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.